Interestingly, the combination of IFNγ and TMZ that mimics the in vivo situation led to similar or even stronger IDO1 upregulation compared to IFNγ alone in two out of four glioma samples (Figure 5). The gene discussed is IDO1; the disease is central nervous system cancer.